Tranexamic Acid in Patients Undergoing Noncardiac Surgery

The POISE-3 trial evaluated the effects of tranexamic acid versus placebo in patients undergoing noncardiac surgery. The study found that tranexamic acid significantly reduced the incidence of life-threatening bleeding, major bleeding, or bleeding into a critical organ (composite bleeding outcome: 9.1% vs. 11.7%, hazard ratio 0.76). However, noninferiority for the composite cardiovascular outcome (myocardial injury, stroke, thrombosis) was not established (14.2% vs. 13.9%, hazard ratio 1.02). Tranexamic acid showed a clear benefit in reducing bleeding without significantly increasing thrombotic risks.

The POISE-3 trial evaluated the effects of tranexamic acid versus placebo in patients undergoing noncardiac surgery. The study found that tranexamic acid significantly reduced the incidence of life-threatening bleeding, major bleeding, or bleeding into a critical organ (composite bleeding outcome: 9.1% vs. 11.7%, hazard ratio 0.76). However, noninferiority for the composite cardiovascular outcome (myocardial injury, stroke, thrombosis) was not established (14.2% vs. 13.9%, hazard ratio 1.02). Tranexamic acid showed a clear benefit in reducing bleeding without significantly increasing thrombotic risks.